Département de Cancérologie Radiothérapie et de Radiophysique, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France.
Radiat Oncol. 2011 Jul 20;6:85. doi: 10.1186/1748-717X-6-85.
To present the results of quality assurance (QA) in IMRT of film dosimetry and ionization chambers measurements with an eight year follow-up.
All treatment plans were validated under the linear accelerator by absolute and relative measures obtained with ionization chambers (IC) and with XomatV and EDR2 films (Kodak).
The average difference between IC measured and computed dose at isocenter with the gantry angle of 0° was 0.07 ± 1.22% (average ± 1 SD) for 2316 prostate, 1.33 ± 3.22% for 808 head and neck (h&n), and 0.37 ± 0.62% for 108 measurements of prostate bed fields. Pelvic treatment showed differences of 0.49 ± 1.86% in 26 fields for prostate cases and 2.07 ± 2.83% in 109 fields of anal canal.Composite measurement at isocenter for each patient showed an average difference with computed dose of 0.05 ± 0.87% for 386 prostate, 1.49 ± 1.86% for 158 h&n, 0.37 ± 0.34% for 23 prostate bed, 0.80 ± 0.28% for 4 pelvis, and 2.31 ± 0.56% for 17 anal canal cases. On the first 250 h&n analyzed by film in absolute dose, the average of the points crossing a gamma index 3% and 3 mm was 93%. This value reached 99% for the prostate fields.
More than 3500 beams were found to be within the limits defined as validated for treatment between 2001 and 2008.
呈现八年随访的膜剂量学和电离室测量的调强放疗（IMRT）质量保证（QA）结果。
所有治疗计划都通过直线加速器进行验证，通过电离室（IC）和 XomatV 和 EDR2 胶片（柯达）获得绝对和相对测量值。
在 0°机架角时，IC 测量的剂量与计算剂量的平均差值在前列腺 2316 例、头颈部（h&n）808 例中分别为 0.07±1.22%（平均值±1 个标准差）和 1.33±3.22%，前列腺床场 108 次测量中分别为 0.37±0.62%。盆腔治疗中，前列腺病例 26 个场的差值为 0.49±1.86%，肛门管 109 个场的差值为 2.07±2.83%。每个患者的等中心复合测量显示，与计算剂量的平均差值在前列腺 386 例中为 0.05±0.87%，在 h&n 158 例中为 1.49±1.86%，在前列腺床 23 例中为 0.37±0.34%，在骨盆 4 例中为 0.80±0.28%，在肛门管 17 例中为 2.31±0.56%。在使用胶片进行的前 250 例 h&n 中，3%和 3mm 伽玛指数交叉点的平均值为 93%。这个值对于前列腺场达到了 99%。
在 2001 年至 2008 年间，超过 3500 束光束被认为在经过验证的治疗范围内。
